Form 4: Cidara Therapeutics Director Acquires Stock Options

Director Theodore R. Schroeder acquired 20,500 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

Summary

• Theodore R. Schroeder, a director at Cidara Therapeutics, Inc., acquired 20,500 stock options on December 17, 2024.
• These options have an exercise price of $22.81.
• The options vest in 36 equal monthly installments starting from December 17, 2024.
• The options expire on December 16, 2034.

Sentiment

Score: 6

Explanation: The document is a routine filing of a stock option grant to a director. It is neither particularly positive nor negative, but it does indicate that a director has a vested interest in the company's performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 36 months is also a typical vesting period for such grants.
• The exercise price of $22.81 is specific to Cidara Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, as the value of the options is tied to the company's stock performance.

Key Dates

Keywords

stock options, insider trading, director, Cidara Therapeutics, CDTX, equity